Company intelligence / Profile preview

Immune Technologies & Medicine

New York, NY, USAaact.ctti-clinicaltrials.org ↗

Ownership: Private
Development stage: Other

Overview

Immune Technology Corp. develops and supplies primary antibodies, recombinant proteins, viral/bacterial antigens, and tumor markers for research use. Their catalog includes products related to COVID-19/SARS-CoV‑2 spike variants, seasonal flu viruses per WHO recommendations for vaccine composition, and Zika virus. The company does not appear to have clinical drug candidates but provides critical tools for life science R&D.

Therapeutic areas: Infectious Diseases
Modalities: Recombinant proteinAntibody
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on Immune Technologies & Medicine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immune Technologies & Medicine.

Explore the full profile